• Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer
  • Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports
  • Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status
  • Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer
  • Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapy
  • Tebentafusp Prolongs Life for Those With Advanced Eye Cancer, Trial Finds
  • EU Approval Urged for Bavencio as Maintenance Therapy for Bladder Cancer
  • Keytruda Approval Recommended in EU as First-line Therapy for Certain Colorectal Cancers
  • Yescarta Shows Promise in Advanced Non-Hodgkin Lymphomas, Trial Data Show
  • Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Show
  • FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer
  • Keytruda-Lenvima Combo in Kidney Cancer Better Than Sutent in Improving Survival